---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011468"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:43:17.835604+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protalix Q2 2025: Revenue $15.4M (+16% YoY), net income $164K; CFO transition, PRX-115 trial on track

## Summary
- Revenue from goods $15.4M (+16% YoY); net income $164K vs $2.2M loss, EPS $0.00.
- Elfabrio sales to Chiesi up $8M; EMA reviews label extension for every-4-weeks dosing.
- CFO Eyal Rubin steps down Aug 24, replaced by Gilad Mamlok; transition through October.
- PRX-115 Phase 2 for uncontrolled gout planned H2 2025; first patient enrollment Q4 2025.
- Cash $33.4M; R&D doubled to $6M on PRX-115 prep; added to Russell 2000/3000 indexes.

## SEC filing metadata
- accession: 0001558370-25-011468
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837025011468/0001558370-25-011468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837025011468/plx-20250814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011468
- JSON: https://secwatch.observer/filing/0001558370-25-011468.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.